EBS Q4 2025 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$149M-23.6% YoY

Gross Profit

$42M28.0% margin

Operating Income

-$6M-4.0% margin

Net Income

-$55M-36.7% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

-35.7%

Cash Flow

Operating Cash Flow

$78M

Free Cash Flow

$74M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$796M

Stockholders' Equity

$523M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$149M	$195M	-23.6%
Gross Profit	$42M	$137M	-69.5%
Operating Income	-$6M	-$10M	+37.9%
Net Income	-$55M	-$31M	-74.4%

Revenue Segments

Product

$144M97%

Contracts and Grants

$5M3%